Cancer Treatment Reviews
Volume 30, Issue 5 , Pages 483-487 , August 2004

Autologous bone marrow transplantation improves disease free survival but not overall survival in people with acute myeloid leukaemia: Abstracted from: Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. Journal of the National Cancer Institute 2004;96:38–45.

  • Thomas R. Chauncey, MD, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. VA Puget Sound Health Care System, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

References 

  1. Burnett AK. Which patients with acute myeloid leukemia should receive a bone marrow transplantation? – an adult treater’s view. Br. J. Haematol. 2002;118:357–364
  2. Wheatley K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? – a statistician’s view. Br. J. Haematol. 2002;118:351–356
  3. Burnett AK, Goldstone AH, Stevens RM, et al.  Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet. 1998;351:700–708
  4. Cassileth PA, Harrington DP, Appelbaum FR, et al.  Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. 1998;339:1649–1656
  5. Harousseau JL, Cahn JY, Pignon B, et al.  Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997;90:2978–2986
  6. Reiffers J, Stoppa AM, Attal M, et al.  Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 88 study. Leukemia. 1996;1874–1882
  7. Zittoun RA, Mandelli F, Willemze R, et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattic Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N. Engl. J. Med. 1995;332:217–223
  8. Slovak ML, Kopecky KJ, Cassileth PA, et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083
  9. Wheatley K, Burnett AK, Goldstone AH, et al.  A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br. J. Haematol. 1999;107:69–79
  10. Linker CA, Ries CA, Damon LE, et al.  Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol. Blood Marrow Transplant. 2000;6:50–57
  11. Gorin NC. Autologous stem cell transplantation for adult acute leukemia. Curr. Opin. Oncol. 2002;14:152–159
  12. Bullinger L, Dohner K, Bair E, et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 2004;350:1605–1616
  13. Valk PJM, Verhaak RGW, Beijen MA, et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004;350:1617–1628

☆ Sources of funding: This study was supported by the Scotiabank Clinician Scientist Training Fund, the Canadian Institutes for Health Research and The Hospital for the Sick Children Clinician Scientist Program.

☆☆ Abstract provided by Bazian Ltd., London.][For correspondence: Lillian Sung, The Hospital for the Sick Children, Division of Haematology/Oncology, University Avenue, Toronto, Ont., Canada. E-mail:lillian.sung@sickkids.ca.

PII: S0305-7372(04)00098-2

doi: 10.1016/j.ctrv.2004.05.005

Cancer Treatment Reviews
Volume 30, Issue 5 , Pages 483-487 , August 2004

Article Tools